Nanoparticle Technology Outsmarts The Brain Cancer Mechanism

Nanoparticles and inhibitors are found to break the shield that brain tumors (like gliomas) build against the immune response by overcoming the blood-brain barrier as per a study in mouse models at the University of Michigan Rogel Cancer Center, published in the journal ACS Nano.

Gliomas are aggressive brain tumors that are often resistant to traditional therapies, by suppressing the immune system and rendering new immune-based therapies ineffective.

‘New nanoparticle approach helps outsmart the defense mechanism of brain cancer by triggering the immune system.

The presence of the blood-brain barrier (the physiological barrier between the brain and its blood vessels) further adds to the challenge to deliver effective treatments to these tumors.

Can Your Treat Gliomas?

The team identified a small molecule (AMD3100) that blocked a key pathway in brain tumors (action of CXCR12, a cytokine released by the glioma cells) and further fabricated a nanoparticle (that contained the inhibitor) to cross the blood-brain barrier (the physiological barrier between the brain and its blood vessels) for its efficacy.

The drug successfully turned on the immune system to eliminate cancer, but the process triggered immune memory so that a reintroduced tumor was also eliminated—a sign that this potential new approach could not only treat brain tumors but prevent or delay recurrences.

Hence, the study showed that AMD3100 successfully helped prevent CXCR12 from binding with immune-suppressive myeloid cells.

Breakthrough Treatment for Brain Tumors

“No one could get this molecule into the brain. It’s really a huge milestone. Outcomes for patients with glioma have not improved for the last 30 years,” says Maria G. Castro, Michigan Medicine.

Further studies in mice and patient cell lines demonstrated that coupling the AMD3100 nanoparticle with radiation therapy enhanced the effect beyond either the nanoparticle or radiation alone.

The team recommends additional safety testing that is necessary before moving to a clinical trial.

Source: Medindia

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – admin@techilive.in. The content will be deleted within 24 hours.
Exit mobile version